[go: up one dir, main page]

PE20091725A1 - Activadores piridazinona de la glucoquinasa - Google Patents

Activadores piridazinona de la glucoquinasa

Info

Publication number
PE20091725A1
PE20091725A1 PE2009000523A PE2009000523A PE20091725A1 PE 20091725 A1 PE20091725 A1 PE 20091725A1 PE 2009000523 A PE2009000523 A PE 2009000523A PE 2009000523 A PE2009000523 A PE 2009000523A PE 20091725 A1 PE20091725 A1 PE 20091725A1
Authority
PE
Peru
Prior art keywords
alkyl
cyclopentil
pyridazin
oxo
aryl
Prior art date
Application number
PE2009000523A
Other languages
English (en)
Inventor
Steven Joseph Berthel
Nancy-Ellen Haynes
Robert Francis Kester
Lee Apostle Mcdermott
Yimin Qian
Ramakanth Sarabu
Nathan Robert Scott
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091725A1 publication Critical patent/PE20091725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIDAZINONA DE FORMULA (I), DONDE X ES O, NR, S, ENTRE OTROS; R ES H O ALQUILO C1-C9; Q ES H, O-ARILO C6-C12; Y ES H, O CUANDO X ES O, Y ES H, HALOGENO, ALQUILO C1-C9, ARILO C6-C12; R1 ES H, ALQUILO C1-C9, CICLOALQUILO C3-C10, ENTRE OTROS; R2 ES ALQUILO C1-C9, CICLOALQUILO C3-C10, ARILO C6-C12, ENTRE OTROS; R3 ES ALQUIL C1-C9-CARBAMOILO O HETEROARILO DE 5 A 12 ATOMOS OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C9, CARBOXILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-{3-CICLOPENTIL-2-[4-(2,6-DIFLUORO-FENOXI)-6-OXO-6H-PIRIDAZIN-1-IL]-PROPIONILAMINO}-NICOTINATO DE METILO, ACIDO 6-{3-CICLOPENTIL-2-[4-(2-FLUORO-FENOXI)-6-OXO-6H-PIRIDAZIN-1-IL]PROPIONILAMINO}-NICOTINICO, 3-CICLOPENTIL-N-[1-((R)-2,3-DIHIDROXI-PROPIL)-1H-PIRAZOL-3-IL]-2-[4-(1H-INDOL-4-ILOXI)-6-OXO-6H-PIRIDAZIN-1-IL]-PROPIONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE LA GLUCOQUINASA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES METABOLICAS TAL COMO DIABETES MELLITUS TIPO II
PE2009000523A 2008-04-16 2009-04-15 Activadores piridazinona de la glucoquinasa PE20091725A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4531808P 2008-04-16 2008-04-16
US11465408P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
PE20091725A1 true PE20091725A1 (es) 2009-11-13

Family

ID=40666944

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000523A PE20091725A1 (es) 2008-04-16 2009-04-15 Activadores piridazinona de la glucoquinasa

Country Status (14)

Country Link
US (1) US8258134B2 (es)
EP (1) EP2268633A1 (es)
JP (1) JP5301655B2 (es)
KR (1) KR101270389B1 (es)
CN (1) CN102007116B (es)
AR (1) AR071323A1 (es)
AU (1) AU2009237792B2 (es)
BR (1) BRPI0911476A2 (es)
CA (1) CA2720559A1 (es)
IL (1) IL207349A (es)
MX (1) MX2010009922A (es)
PE (1) PE20091725A1 (es)
TW (1) TW200944517A (es)
WO (1) WO2009127544A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
MX2009008531A (es) * 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
JP5946992B2 (ja) 2008-02-29 2016-07-06 ランセウス メディカル イメージング， インコーポレイテッド 灌流造影を含む適用のための造影剤
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
CA2789044C (en) 2010-02-08 2020-09-15 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP3936608B1 (en) 2010-03-31 2025-05-07 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TWI566663B (zh) * 2011-03-15 2017-01-11 鴻海精密工業股份有限公司 鎖扣組件、帶有鎖扣組件的載具及電路板固定系統
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
AR127064A1 (es) * 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd Prodroga de derivados de pirrolidona como activador de glucoquinasa
WO2024132901A1 (en) * 2022-12-19 2024-06-27 Syngenta Crop Protection Ag Microbiocidal pyridazine dihydrooxadiazine derivatives
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1169312E (pt) 1999-03-29 2005-01-31 Hoffmann La Roche Activadores de glicocinase
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
US6388071B2 (en) 2000-05-03 2002-05-14 Hoffmann-La Roche Inc. Alkynyl phenyl heteroaromatic glucokinase activators
CA2407763C (en) 2000-05-08 2007-04-24 Fred Thomas Bizzarro Para-amine substituted phenylamide glucokinase activators
MXPA02010796A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa.
DE60117059T2 (de) 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1458382A1 (en) * 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
JP4091600B2 (ja) 2002-04-26 2008-05-28 エフ．ホフマン−ラ ロシュ アーゲー 置換フェニルアセトアミド及びグルコキナーゼ活性化物質としてのその使用
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
US7812167B2 (en) 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
GT200300283A (es) * 2002-12-12 2004-07-14 Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
EP1718625A1 (en) 2004-02-18 2006-11-08 AstraZeneca AB Compounds
ES2322709T3 (es) 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
WO2005090332A1 (ja) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd 置換キナゾリン又はピリドピリミジン誘導体
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR20080105180A (ko) 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR101066882B1 (ko) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
AU2006285834A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
BRPI0618062A2 (pt) 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
SI2463283T1 (sl) 2006-04-20 2014-09-30 Pfizer Products Inc. Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza
KR20080042286A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리다지논 구조를 포함하는 캐스파제 저해제
CL2008002703A1 (es) * 2007-09-14 2009-11-20 Sumitomo Chemical Co Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
WO2009142732A2 (en) * 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
AU2009237792B2 (en) 2014-07-24
MX2010009922A (es) 2010-09-28
IL207349A0 (en) 2010-12-30
JP5301655B2 (ja) 2013-09-25
TW200944517A (en) 2009-11-01
KR101270389B1 (ko) 2013-06-05
AR071323A1 (es) 2010-06-09
WO2009127544A1 (en) 2009-10-22
BRPI0911476A2 (pt) 2019-03-19
US20090264434A1 (en) 2009-10-22
EP2268633A1 (en) 2011-01-05
AU2009237792A1 (en) 2009-10-22
CN102007116A (zh) 2011-04-06
CN102007116B (zh) 2014-10-22
CA2720559A1 (en) 2009-10-22
IL207349A (en) 2014-08-31
JP2011516592A (ja) 2011-05-26
KR20100124328A (ko) 2010-11-26
US8258134B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
PE20091725A1 (es) Activadores piridazinona de la glucoquinasa
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20130039A1 (es) Pirazoles fungicidas
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
NO20081821L (no) Forbindelser for behandling av metabolske forstyrrelser
PE20110328A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20121519A1 (es) Compuestos de pirazol como antagonistas de crth2
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20130590A1 (es) Derivados de tomaimicina como agentes citotoxicos
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
MX2014000359A (es) Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii.
PE20140934A1 (es) Derivados de pirazol
NO20084350L (no) Heterocykliske amider til anvendelse som farmasoytika
PE20090226A1 (es) PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
AR082519A1 (es) Fenilamidinas que tienen alta actividad fungicida, y su utilizacion
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico

Legal Events

Date Code Title Description
FD Application declared void or lapsed